FDA Enforcement Class II Terminated

AIA-360 Analyzer is capable of performing two methods of immunoassay: an immunoenzymetric (IEMA) or sandwich immunoassay, a competitive binding (EIA) immunoassay. An antigen-antibody reaction begins by combining a patient sample, control, or calibrator with a diluent in an immunoreaction test cup from the AIA-PACK reagent series.

Recall: Z-0613-2019 · Reported December 26, 2018

Enforcement

Recall Number
Z-0613-2019
Event ID
81170
Classification
Class II
Status
Terminated
Product Type
Devices
Firm
Tosoh Bioscience Inc
Voluntary / Mandated
Voluntary: Firm initiated
Initial Notification
Letter
Report Date
December 26, 2018
Initiation Date
March 22, 2017
Classification Date
December 14, 2018
Termination Date
December 9, 2020
Address
3600 Gantz Rd, Grove City, OH, 43123-1895, United States

Description

AIA-360 Analyzer is capable of performing two methods of immunoassay: an immunoenzymetric (IEMA) or sandwich immunoassay, a competitive binding (EIA) immunoassay. An antigen-antibody reaction begins by combining a patient sample, control, or calibrator with a diluent in an immunoreaction test cup from the AIA-PACK reagent series.

Reason

The firm has become aware of a potential issue with the AIA-360 analyzer that could prevent the table home sensor from detecting the table home position. If the malfunction with the table home sensor occurs on the AIA-360, the sensor board may need to be replaced. If the home sensor fails to detect the home position, the AIA-360 analyzer will cease to function and will be unavailable for use. If this issue occurs, there may be a delay in testing and reporting patient test results. Tosoh has received three (3) complaints related to this issue with no serious injuries reported.

Code Info

All units with serial numbers prior to "1701"

Distribution

Nationwide distribution. International distribution to Honduras, Caribbean, Chile, Colombia, Costa Rica, Uruguay, Ecuador, Panama, Mexico, Canada, and Venezuela.

Quantity

438